cyclosporine + dexamethasone + rituximab

This drug is a combination therapy consisting of three agents: - **Cyclosporine** is a small molecule immunosuppressant that acts as a calcineurin inhibitor, preventing T-cell activation by inhibiting the phosphatase activity of calcineurin. It is used to prevent organ transplant rejection and treat autoimmune and inflammatory conditions. - **Dexamethasone** is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressive effects. It modulates gene expression to reduce inflammation and immune responses. - **Rituximab** is a chimeric monoclonal antibody targeting CD20 on B cells, leading to B cell depletion through mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity. It treats various B-cell malignancies, autoimmune diseases like rheumatoid arthritis, and other immune disorders. The combination leverages complementary immunosuppressive mechanisms targeting both T cells (cyclosporine), broad anti-inflammatory effects (dexamethasone), and B cells (rituximab). This triple therapy has been investigated primarily for refractory immune thrombocytopenia (ITP) with promising efficacy in inducing durable remissions after short treatment duration. It has also been explored in other autoimmune or hematologic conditions requiring combined immunosuppression.

Other names

CyDRi regimenTT4 regimenTT-4 regimenTT 4 regimen